Project Grant R01CA315741
Award Date 8/1/26
Completion Date 7/31/31
Dollars Obligated $650K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Madison, WI 53715, USA
Similar Awards
- The National Cancer Institute awarded the University of Wisconsin–Madison $113,766 on January 12, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support research combining antigen-specific vaccination with radiopharmaceutical therapy to enhance anti-tumor immunity against metastatic castration-resistant prostate cancer. The project investigates combined treatment using an anti-tumor vaccine to prime tumor-specific CD8+ T cells, followed by radiopharmaceutical therapy targeting...
- The National Cancer Institute, a division of the Department of Health and Human Services National Institutes of Health, awarded University of Wisconsin–Madison $634,791 on July 3, 2026, under the Cancer Treatment Research program (CFDA 93.395) for development of shark antibody radiopharmaceuticals (SHARPs) targeting lineage plasticity in castration-resistant prostate cancer. The funded work develops bispecific antibody constructs that engage two antigens simultaneously to overcome treatment...
- The National Cancer Institute awarded Northwestern University $660,525 in project grant funding on August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to engineer immunostimulatory spherical nucleic acids for B cell adoptive therapy against prostate cancer. The funded research develops a novel strategy to sensitize immunologically "cold" prostate tumors to immune checkpoint blockade by training peripheral B cells ex vivo with immunostimulatory spherical nucleic...
- The National Cancer Institute awarded the University of Wisconsin–Madison $627,628 on July 20, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop and test a novel anti-fibrotic peptide therapy for metastatic triple-negative breast cancer. The funded research develops PEG-FUD, a pegylated peptide that targets and inhibits fibronectin assembly in the tumor microenvironment. Excess fibronectin deposition in tumors limits chemotherapy penetration, excludes immune cell...
- The National Cancer Institute awarded the University of Pittsburgh $658,492 on March 18, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop a novel targeted combinatorial therapy for castration-resistant prostate cancer. The award funds research into hyaluronic acid-based nanocarriers co-loaded with the CHK1 inhibitor SRA737 and the WEE1 inhibitor AZD1775 for targeted treatment of advanced castration-resistant prostate cancer (ACRPC), including crpc-adeno and nepc...
- The National Cancer Institute, part of the Department of Health and Human Services, awarded The Johns Hopkins University $658,423 on July 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to conduct research on therapeutic targeting of PI3K-gamma-positive tumor-associated macrophages in metastatic castration-resistant prostate cancer with the goal of reducing health disparities. The research addresses the role of tumor-associated macrophages (TAMs) in suppressing immune response...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded the University of California, Los Angeles a $404,972 Project Grant effective August 1, 2025, through July 31, 2027, under the Cancer Treatment Research program (CFDA 93.395). This award supports fundamental and applied research investigating mechanisms of radiopharmaceutical therapy (RPT) resistance in metastatic castration-resistant prostate cancer. The research will evaluate how the ectonucleotidase enzyme ENPP1...
- Federal Project Grant Award Summary The University of Wisconsin-Madison received a $603,981 Project Grant from the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) awarded August 18, 2025, with completion targeted for July 31, 2030. This research initiative develops and validates integrated clinical-grade artificial intelligence (AI) biomarkers combining genomic and digital pathology analysis to improve risk stratification and treatment...
- The National Cancer Institute, part of the National Institutes of Health, awarded $508,651 to the University of Wisconsin–Madison on June 2, 2026, under the Cancer Biology Research program (CFDA 93.396) to define and exploit therapeutically the role of neuropeptide receptor PAC1 in tumor-infiltrating pericytes during melanoma progression. The research investigates how PACAP-expressing neurons within the melanoma microenvironment interact with PAC1-expressing pericytes to drive disease...
- The National Institutes of Health National Cancer Institute awarded H. Lee Moffitt Cancer Center And Research Institute Hospital, Inc. $589,581 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to optimize gamma/delta CAR-T-cell therapy for bone metastatic castration-resistant prostate cancer. The award funds research to advance a novel immunotherapy combining autologous chimeric antigen receptor T-cell infusions with zoledronate treatment in metastatic...